HCV treatment uptake in people who have injected drugs — observations in a large cohort that received addiction treatment 1970–1984
Authors:
- Ellen J. AmundsenEAEllen J. Amundsen
- Olav DalgardODOlav Dalgard
- 13 October 2014
- journal article
- research article
- Published by Taylor & Francis in Scandinavian Journal of Gastroenterology
- Vol. 49 (12) , 1465-1472
Abstract
Objectives. The aim of this study was to document antiviral treatment uptake among former or current people who inject drugs (PWID) with chronic hepatitis C and to explore a possible association between treatment and mortality. Material and methods. This is a longitudinal cohort study of PWID admitted for drug abuse treatment 1970–1984. The 245 hepatitis C virus (HCV) RNA-positive patients alive by the end of 1996 were followed 1997–2012 through linkage to several health registers. Treatment uptake was mainly documented by information on prescription of antiviral medication registered in the Norwegian Prescription Database from 2004. Cox regression, with a time-dependent covariate measuring end-of-treatment, was employed to evaluate mortality after treatment. Results. At the end of the follow-up, median time since HCV exposure was 36 years, and 19.2% (47/245) had been prescribed antiviral treatment for chronic HCV infection. No gender difference was observed. Among those alive at the end of the study period, 27.8% (44/158) had been treated. Relative hazard of death was 0.21 (95% confidence interval [CI] 0.07–0.68), comparing periods for patients after versus before or without treatment. Mortality rate after treatment was 0.8 per 100 person years (95% CI 0.3–2.4) compared to 2.8 (95% CI 2.2–3.5) in untreated patients and before treatment. The most important causes of death among the untreated were drug-related. Conclusions. Among PWID infected with HCV, approximately one-fourth of those still alive at a median of 36 years after exposure had received HCV treatment. Treatment was associated with increased survival, probably mainly due to selection bias.Keywords
This publication has 32 references indexed in Scilit:
- A Sustained Virologic Response Reduces Risk of All-Cause Mortality in Patients With Hepatitis CClinical Gastroenterology and Hepatology, 2011
- A Systematic Review and Meta-Analysis of Interventions to Prevent Hepatitis C Virus Infection in People Who Inject DrugsThe Journal of Infectious Diseases, 2011
- Hepatitis C testing and treatment among active drug users in AmsterdamEuropean Journal of Gastroenterology & Hepatology, 2011
- Nye retningslinjer for utredning og behandling av hepatitt CTidsskrift for Den norske legeforening, 2011
- A Sustained Viral Response Is Associated With Reduced Liver-Related Morbidity and Mortality in Patients With Hepatitis C VirusClinical Gastroenterology and Hepatology, 2010
- Factors associated with uptake of treatment for recent hepatitis C virus infection in a predominantly injecting drug user cohort: The ATAHC StudyDrug and Alcohol Dependence, 2010
- Low uptake of treatment for hepatitis C virus infection in a large community‐based study of inner city residentsJournal of Viral Hepatitis, 2009
- The epidemiology of hepatitis C infection in the United StatesJournal of Gastroenterology, 2007
- Rate and predictors of treatment prescription for hepatitis CGut, 2006
- Improvement of HCV genome detection with "short" PCR productsThe Lancet, 1991